Disease-modifying antirheumatic drugs (DMARDs)

DRUG3 trials

Sponsors

Hoffmann-La Roche, Astellas Pharma China, Inc., Fundación Santa Fe de Bogota

Conditions

Covid19Rheumatic DiseasesRheumatoid ArthritisRheumatoid Arthritis (RA)

Phase 3

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

CompletedNCT01194414

Hoffmann-La RocheRheumatoid Arthritis

Start: 2010-09-30End: 2013-08-31Updated: 2016-06-20

A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)

CompletedNCT03660059

Astellas Pharma China, Inc.Rheumatoid Arthritis (RA)

Start: 2018-09-27End: 2021-11-02Updated: 2024-10-21

Unknown Phase

Predictive Factors for COVID-19 in Rheumatology

Fundación Santa Fe de BogotaCovid19, Rheumatic Diseases

Start: 2020-10-31End: 2021-10-31Target: 150Updated: 2020-09-28

Related Papers

Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study.

2023-10-185 citations

Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects

Drug Design Development and Therapy2022-05-013 citations

Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan

Arthritis Research & Therapy2020-03-1229 citations

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis.

2018-06-1712 citations

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Lara D. Veeken2017-10-3137 citations

Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study

Rheumatology and Therapy2016-09-2424 citations

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

Annals of the Rheumatic Diseases2015-06-09122 citations